Study #2024-0022
Phase II randomized, placebo- controlled study of intralesional nivolumab for high-risk oral premalignant lesions
MD Anderson Study Status
Enrolling
Treatment Agent
Nivolumab
Description
To evaluate the antitumor efficacy of intralesional injections of nivolumab in patients with high-risk oral premalignant lesions
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Premalignant Lesion
Study phase:
Phase II
Physician name:
Moran Amit
Department:
Head & Neck Surgery
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.